# Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

> **NCT01873885** · PHASE1 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 20 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Placebo Single IV (Intravenous) Infusion
- **DRUG:** Experimental: Single IV Infusion Vasomera (PB1046)

## Key facts

- **NCT ID:** NCT01873885
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873885, "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01873885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*